Long-term prognostic outcomes in patients with haemoptysis
Abstract Background Haemoptysis is a challenging symptom that can be associated with potentially life-threatening medical conditions. Follow-up is key in these patients to promptly detect new or misdiagnosed pathologic findings. Few prospective studies have evaluated long-term prognostic outcomes in...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-08-01
|
| Series: | Respiratory Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12931-021-01809-6 |
| _version_ | 1819128792234328064 |
|---|---|
| author | Michele Mondoni Paolo Carlucci Giuseppe Cipolla Matteo Pagani Francesco Tursi Alessandro Fois Pietro Pirina Sara Canu Stefano Gasparini Martina Bonifazi Silvia Marani Andrea Comel Laura Saderi Sabrina De Pascalis Fausta Alfano Stefano Centanni Giovanni Sotgiu |
| author_facet | Michele Mondoni Paolo Carlucci Giuseppe Cipolla Matteo Pagani Francesco Tursi Alessandro Fois Pietro Pirina Sara Canu Stefano Gasparini Martina Bonifazi Silvia Marani Andrea Comel Laura Saderi Sabrina De Pascalis Fausta Alfano Stefano Centanni Giovanni Sotgiu |
| author_sort | Michele Mondoni |
| collection | DOAJ |
| description | Abstract Background Haemoptysis is a challenging symptom that can be associated with potentially life-threatening medical conditions. Follow-up is key in these patients to promptly detect new or misdiagnosed pathologic findings. Few prospective studies have evaluated long-term prognostic outcomes in patients with haemoptysis. Furthermore, the role played by antiplatelet and anticoagulant drugs on mortality and recurrence rates is unclear. The aim of this study was to assess mortality after 18 months of follow-up. Furthermore, the incidence of recurrence and the risk factors for recurrence and death were evaluated (including the role played by anticoagulant and antiplatelet drugs). Methods Observational, prospective, multicentre, Italian study. Results 451/606 (74.4%) recruited patients with haemoptysis completed the 18 months follow-up. 22/604 (3.6%) diagnoses changed from baseline to the end of the follow-up. 83/604 (13.7%) patients died. In 52/83 (62.7%) patients, death was the outcome of the disease which caused haemoptysis at baseline. Only the diagnosis of lung neoplasm was associated with death (OR (95%CI): 38.2 (4.2–347.5); p-value: 0.0001). 166 recurrences were recorded in 103/604 (17%) patients. The diagnosis of bronchiectasis was significantly associated with the occurrence of a recurrence (OR (95% CI): 2.6 (1.5–4.3)); p-value < 0.0001). Anticoagulant, antiaggregant, and anticoagulant plus antiaggregant drugs were not associated with an increased risk of death and recurrence. Conclusions Our study showed a low mortality rate in patients with haemoptysis followed-up for 18 months. Pulmonary malignancy was the main aetiology and the main predictor of death, whereas bronchiectasis was the most frequent diagnosis associated with recurrence. Antiplatelet and/or anticoagulant therapy did not change the risk of death or recurrence. Follow-up is recommended in patients initially diagnosed with lower airways infections and idiopathic bleeding. Trial registration: NCT02045394 |
| first_indexed | 2024-12-22T08:33:27Z |
| format | Article |
| id | doaj.art-aed485b5d31547549f2a93c579867bca |
| institution | Directory Open Access Journal |
| issn | 1465-993X |
| language | English |
| last_indexed | 2024-12-22T08:33:27Z |
| publishDate | 2021-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj.art-aed485b5d31547549f2a93c579867bca2022-12-21T18:32:26ZengBMCRespiratory Research1465-993X2021-08-012211710.1186/s12931-021-01809-6Long-term prognostic outcomes in patients with haemoptysisMichele Mondoni0Paolo Carlucci1Giuseppe Cipolla2Matteo Pagani3Francesco Tursi4Alessandro Fois5Pietro Pirina6Sara Canu7Stefano Gasparini8Martina Bonifazi9Silvia Marani10Andrea Comel11Laura Saderi12Sabrina De Pascalis13Fausta Alfano14Stefano Centanni15Giovanni Sotgiu16Respiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di MilanoRespiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di MilanoUOC Pneumologia, ASST LodiUO Pneumologia ed Endoscopia Toracica, Azienda Ospedaliero Universitaria di ParmaUOS Servizio Pneumologia, Ospedale di Codogno, ASST LodiLung Disease Unit, Dept of Clinical and Experimental Medicine, University of SassariLung Disease Unit, Dept of Clinical and Experimental Medicine, University of SassariLung Disease Unit, Dept of Clinical and Experimental Medicine, University of SassariPulmonary Disease Unit, Department of Internal Medicine, Azienda Ospedali Riuniti, Department of Biomedical Sciences and Public Health, Università Politecnica Delle MarchePulmonary Disease Unit, Department of Internal Medicine, Azienda Ospedali Riuniti, Department of Biomedical Sciences and Public Health, Università Politecnica Delle MarcheUO Medicina Interna, AUSL Modena, Ospedale di CarpiUO PneumologiaClinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of SassariRespiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di MilanoRespiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di MilanoRespiratory Unit, ASST Santi Paolo e Carlo, San Paolo Hospital, Department of Health Sciences, Università degli Studi di MilanoClinical Epidemiology and Medical Statistics Unit, Dept of Medical, Surgical and Experimental Sciences, University of SassariAbstract Background Haemoptysis is a challenging symptom that can be associated with potentially life-threatening medical conditions. Follow-up is key in these patients to promptly detect new or misdiagnosed pathologic findings. Few prospective studies have evaluated long-term prognostic outcomes in patients with haemoptysis. Furthermore, the role played by antiplatelet and anticoagulant drugs on mortality and recurrence rates is unclear. The aim of this study was to assess mortality after 18 months of follow-up. Furthermore, the incidence of recurrence and the risk factors for recurrence and death were evaluated (including the role played by anticoagulant and antiplatelet drugs). Methods Observational, prospective, multicentre, Italian study. Results 451/606 (74.4%) recruited patients with haemoptysis completed the 18 months follow-up. 22/604 (3.6%) diagnoses changed from baseline to the end of the follow-up. 83/604 (13.7%) patients died. In 52/83 (62.7%) patients, death was the outcome of the disease which caused haemoptysis at baseline. Only the diagnosis of lung neoplasm was associated with death (OR (95%CI): 38.2 (4.2–347.5); p-value: 0.0001). 166 recurrences were recorded in 103/604 (17%) patients. The diagnosis of bronchiectasis was significantly associated with the occurrence of a recurrence (OR (95% CI): 2.6 (1.5–4.3)); p-value < 0.0001). Anticoagulant, antiaggregant, and anticoagulant plus antiaggregant drugs were not associated with an increased risk of death and recurrence. Conclusions Our study showed a low mortality rate in patients with haemoptysis followed-up for 18 months. Pulmonary malignancy was the main aetiology and the main predictor of death, whereas bronchiectasis was the most frequent diagnosis associated with recurrence. Antiplatelet and/or anticoagulant therapy did not change the risk of death or recurrence. Follow-up is recommended in patients initially diagnosed with lower airways infections and idiopathic bleeding. Trial registration: NCT02045394https://doi.org/10.1186/s12931-021-01809-6HaemoptysisRecurrenceLung cancerBronchoscopyAnticoagulantAntiplatelet |
| spellingShingle | Michele Mondoni Paolo Carlucci Giuseppe Cipolla Matteo Pagani Francesco Tursi Alessandro Fois Pietro Pirina Sara Canu Stefano Gasparini Martina Bonifazi Silvia Marani Andrea Comel Laura Saderi Sabrina De Pascalis Fausta Alfano Stefano Centanni Giovanni Sotgiu Long-term prognostic outcomes in patients with haemoptysis Respiratory Research Haemoptysis Recurrence Lung cancer Bronchoscopy Anticoagulant Antiplatelet |
| title | Long-term prognostic outcomes in patients with haemoptysis |
| title_full | Long-term prognostic outcomes in patients with haemoptysis |
| title_fullStr | Long-term prognostic outcomes in patients with haemoptysis |
| title_full_unstemmed | Long-term prognostic outcomes in patients with haemoptysis |
| title_short | Long-term prognostic outcomes in patients with haemoptysis |
| title_sort | long term prognostic outcomes in patients with haemoptysis |
| topic | Haemoptysis Recurrence Lung cancer Bronchoscopy Anticoagulant Antiplatelet |
| url | https://doi.org/10.1186/s12931-021-01809-6 |
| work_keys_str_mv | AT michelemondoni longtermprognosticoutcomesinpatientswithhaemoptysis AT paolocarlucci longtermprognosticoutcomesinpatientswithhaemoptysis AT giuseppecipolla longtermprognosticoutcomesinpatientswithhaemoptysis AT matteopagani longtermprognosticoutcomesinpatientswithhaemoptysis AT francescotursi longtermprognosticoutcomesinpatientswithhaemoptysis AT alessandrofois longtermprognosticoutcomesinpatientswithhaemoptysis AT pietropirina longtermprognosticoutcomesinpatientswithhaemoptysis AT saracanu longtermprognosticoutcomesinpatientswithhaemoptysis AT stefanogasparini longtermprognosticoutcomesinpatientswithhaemoptysis AT martinabonifazi longtermprognosticoutcomesinpatientswithhaemoptysis AT silviamarani longtermprognosticoutcomesinpatientswithhaemoptysis AT andreacomel longtermprognosticoutcomesinpatientswithhaemoptysis AT laurasaderi longtermprognosticoutcomesinpatientswithhaemoptysis AT sabrinadepascalis longtermprognosticoutcomesinpatientswithhaemoptysis AT faustaalfano longtermprognosticoutcomesinpatientswithhaemoptysis AT stefanocentanni longtermprognosticoutcomesinpatientswithhaemoptysis AT giovannisotgiu longtermprognosticoutcomesinpatientswithhaemoptysis |